Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | C1R | P00736 | 1/20 | 0.51 |
| ▸ | IL6 | P05231 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 1/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 7/20 | 0.48 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2429466 | 0.91 | ITGA4 (0.56) | NPC1RAB9ATP53PKMSMN1; SMN2 | |
| SCHEMBL2434873 | 0.89 | NPC1 (0.58) | NPC1RAB9ATP53PKMSMN1; SMN2 | |
| SCHEMBL2432782 | 0.86 | CSNK1D (0.47) | NPC1RAB9ATP53PKMSMN1; SMN2 | |
| SCHEMBL31430615 | 0.84 | GAA (0.56) | NPC1RAB9APKMSMN1; SMN2GAA | |
| SCHEMBL6593703 | 0.84 | HDAC6 (0.62) | NPC1RAB9APKMSMN1; SMN2GAA | |
| SCHEMBL12327643 | 0.83 | NPC1 (0.63) | NPC1RAB9ATP53PKMSMN1; SMN2 | |
| SCHEMBL4679538 | 0.81 | TP53 (0.47) | NPC1RAB9ATP53PKMSMN1; SMN2 | |
| SCHEMBL31430448 | 0.80 | GAA (0.55) | NPC1RAB9AGAAIL6STAT3 | |
| SCHEMBL5271980 | 0.80 | ITGA4 (0.55) | NPC1RAB9ATP53PKMSMN1; SMN2 | |
| SCHEMBL2435619 | 0.80 | ITGA4 (0.53) | NPC1RAB9ATP53PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | NPC1 1278/4885RAB9A 2530/4885TP53 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.